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Abstract
Summary: Rational design of drug combinations has become a promising strategy to tackle the
drug sensitivity and resistance problem in cancer treatment. To systematically evaluate the pre-
clinical significance of pairwise drug combinations, functional screening assays that probe combin-
ation effects in a dose–response matrix assay are commonly used. To facilitate the analysis of such
drug combination experiments, we implemented a web application that uses key functions of R-
package SynergyFinder, and provides not only the flexibility of using multiple synergy scoring
models, but also a user-friendly interface for visualizing the drug combination landscapes in an
interactive manner.
Availability and Implementation: The SynergyFinder web application is freely accessible at https://
synergyfinder.fimm.fi; The R-package and its source-code are freely available at http://bioconduc
tor.org/packages/release/bioc/html/synergyfinder.html.
Contact: jing.tang@helsinki.fi
1 Introduction
Making cancer treatment more personalized and effective is one of
the grand challenges of our health care system. However, multiple
clinical studies have shown that even when there is a dramatic initial
treatment response, cancer cells with high mutational potential and
functional redundancy can easily develop drug resistance via a net-
work of compensating or bypassing pathways (Knight et al., 2010).
For improved efficacy, there is a critical need to identify drug com-
binations, which target both the cancer driver and bypass signals
(Al-Lazikani et al., 2012).
Recently, high-throughput drug screening has made it possible to
assay a large number of compounds, where a pair of drugs is plated
in a dose–response matrix, thus enabling the assessment of drug
combination effects at various dose levels (Mathews Griner et al.,
2014; Mott et al., 2015). To quantify the degree of synergy or antag-
onism, the combination response is often compared against the
expected combination response, under the assumption of non-
interaction calculated using a reference model (Tang et al., 2015).
Commonly-utilized reference models include the Highest single
agent (HSA) model (Berenbaum, 1989), the Loewe additivity model
(Loewe, 1953), the Bliss independence model (Bliss, 1939), and
more recently, the Zero interaction potency (ZIP) model (Yadav
et al., 2015). The assumptions being made in these reference models
are different from each other, which may produce inconsistent con-
clusions about the degree of synergy. Software tools that allow for
comparison of different reference models are therefore highly
needed for an unbiased analysis of drug combination experiments
(e.g. Di Veroli et al., 2016).
To address these needs, we implemented SynergyFinder, a web
application for the preprocessing and visualization of the drug com-
bination dose–response data. The tool implements synergy scoring
with four major reference models: HSA, Loewe, Bliss and ZIP mod-
els. The degree of a drug combination effect can be readily visualized
as a synergy landscape map over the dose matrix. Dose regions that
show strong synergy or antagonism can be zoomed-in for more de-
tailed analyses and interpretation about clinical feasibility of the
combination. To the best of our knowledge, SynergyFinder intro-
duces the first publicly available web-application based on an open-
source R-package for analyzing high-throughput drug combination
dose–response matrix data.
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2 Implementation
2.1 General overview
The SynergyFinder R package implements algorithms to calculate
synergy scores for dose–response matrix data. Currently, four refer-
ence models are available: (i) HSA model, where the synergy score
quantifies the excess over the highest single drug response; (ii)
Loewe model, where the synergy score quantifies the excess over the
expected response if the two drugs are the same compound; (iii)
Bliss model, where the expected response is a multiplicative effect as
if the two drugs act independently; and (iv) ZIP model, where the
expected response corresponds to an additive effect as if the two
drugs do not affect the potency of each other. Yadav et al., 2015
presented a detailed comparison of these reference model. The
front-end web application offers a user-friendly and interactive
graphical interface for visualization of drug combination data and
the calculated synergy scores either as a two-dimensional or a three-
dimensional synergy map over the dose matrix (Fig. 1).
2.2 Data submission and preprocessing
The default input is a text file that includes the annotations of the
dose–response matrices for drug pairs which include drug names,
concentrations and phenotypic responses. The number of drug com-
binations provided in the input file is unrestricted. For each drug
combination, the dose–response matrix should contain at least three
rows and three columns so that sensible synergy scores can be calcu-
lated. After the input file has been successfully uploaded, the types
of phenotypic responses need to be specified. Thereafter a data visu-
alization tab will be created for each drug combination, where the
user may obtain an overview of the full dose–response matrix, as
well as the dose–response curves for the single drugs, fitted by four-
parameter logistic models. The visualizations enable the user to
identify any problematic data points, such as negative phenotypic re-
sponses or outliers for which a drug combination reference model
may not be properly fitted.
2.3 Calculation of synergy scores and their visualization
Given a reference model specified by the ‘Method’ parameter, an
overall synergy score is calculated as the deviation of phenotypic re-
sponses compared to the expected values, averaged over the full
dose–response matrix. Visualization of the synergy scores may be
obtained by switching on the ‘Visualize synergy scores’ toggle-bar.
In the 2D plot, the user may zoom in by brushing and double-
clicking a certain region, and then save the zoomed synergy map as
a new figure in PDF format. The overall synergy score
corresponding to this selected dose region will be shown accordingly
in the figure caption. In the 3D plot, the individual synergy score at
each dose combination can be displayed by hovering the mouse. The
synergy map can be rotated and downloaded as publication quality
SVG or PNG image or interactive plot in HTML format.
2.4 Reporting
SynergyFinder generates the results in PDF format for all or a subset
of the drug combinations, depending on the user’s choices. The dose
response matrices and the synergy maps can be generated accord-
ingly. The calculated synergy scores can be downloaded as a table.
We provided also an enhanced dynamic report which allows the
user to specify the viewing angle of the 3D synergy map
2.5 Tutorial and feedback
The SynergyFinder web application is implemented using R and
hosted by Open Source Shiny Server. To facilitate its usage, an inter-
active web tour, a video tutorial, a user guide documentation and
example input data can be found on the website. The user may leave
comments or suggestions for improvements using the feedback
form. For the users with R programming experience, the
SynergyFinder R-package provides the source code to run the drug
combination analyses independently of the web application and
allows other developers to extend its key functions.
3 Conclusion
The SynergyFinder web-application facilitates the visualization and
analysis of drug combination data from high-throughput dose–re-
sponse matrix assays. Use of multiple reference models on the full
dose–response matrix should provide an unbiased and straightfor-
ward way to evaluate the pre-clinical significance of drug combin-
ations toward exciting clinical applications.
In the future, we plan to provide more flexibility for analyzing
drug combination data, e.g. by alternative curve-fitting functions for
single drugs and missing value imputation, as well as means to assess
the statistical significance of synergy using replicate measurements.
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Fig. 1. The outcome panels of the SynergyFinder web application. (a) Visualization of the dose–response matrix and the plots of phenotypic responses for the sin-
gle drugs. (b) Visualization of the calculated 2D and 3D synergy maps
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